SharePitch
  • Cleantech & Renewables
  • Gaming
  • Twitter Feed
  • Cleantech & Renewables
  • Gaming
  • Twitter Feed

Stock  and  industry  updates.

​Stories  from  exciting  companies.

Appili Therapeutics Closes $3.5 Million Funding Agreement

8/18/2021

0 Comments

 
Picture
Appili Therapeutics Inc. (TSX: APLI), a biopharmaceutical company focused on drug development for infectious diseases, has closed a $3.5 million convertible security funding agreement.

As part of the deal, Appili received net proceeds of $3.4 million from Lind Global Fund II, LP, an investment entity managed by New York institutional fund manager The Lind Partners. 

Appili Therapeutics intends to use the funding to support the operations of the Company as it prepares for top-line data from its PRESECO Phase 3 trial evaluating Avigan®/Reeqonus™ (favipiravir) as a potential oral therapy for patients with mild-to-moderate COVID-19. The funding will also be used to advance the broader Appili pipeline, including ATI-2307, a novel clinical stage antifungal expected to enter Phase 2 study in 2022.

Source: Appili Therapeutics Inc.
0 Comments



Leave a Reply.

    Follow @SharePitch on Twitter 

    Archives

    March 2022
    February 2022
    November 2021
    September 2021
    August 2021

    Categories

    All
    Agriculture
    Biotech
    Healthcare
    Mining
    Sustainability

    RSS Feed

Terms of Use